(secondQuint)Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's.

 This trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo.

 The study subjects will have the diagnosis of mild dementia of the Alzheimer's type.

 Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.

 The primary objective of the study is to evaluate the change in cognition and activities of daily living.

.

 Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's@highlight

The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.

